Table 2.
Analysis of sustained virological response (SVR) and comparison of patients treated with sofosbuvir and daclatasvir versus sofosbuvir and simeprevir.
| SOF + DCV ± RBV, % (n = 176) | SOF + SMV ± RBV, % (n = 79) | p-Value a | |
|---|---|---|---|
| Overall SVR % | 90.9 (160/176) | 92.4 (73/79) | 0.69 |
| Genotype | |||
| 1 unspecified | 92.3 (24/26) | 87.5 (7/8) | 0.67 |
| 1a | 91.6 (33/36) | 94.8 (37/39) | 0.57 |
| 1b | 100 (40/40) | 90.3 (28/31) | 0.04 |
| GT1 total | 95.0 (97/102) | 92.4 (73/79) | 0.45 |
| 3 | 84.7 (61/72) | – | NA |
| Cirrhosis yes | 92.2 (71/77) | 90.9 (20/22) | 0.84 |
| Cirrhosis no | 89.4 (34/38) | 93.7 (30/32) | 0.52 |
| Cirrhosis NI | 90.1 (55/61) | 92.0 (23/25) | 0.79 |
| Treatment naïve | 95.1 (79/83) | 97.5 (40/41) | 0.52 |
| Treatment experienced | 86.9 (80/92) | 85.7 (30/35) | 0.85 |
| Treatment 12 weeks | 89.1(115/129) | 93.5 (72/77) | 0.29 |
| Treatment 24 weeks | 95.4 (42/44) | 50.0 (1/2) | 0.01 |
| With RBV | 94.6 (53/56) | 87.5 (7/8) | 0.50 |
| Without RBV | 88.4 (100/113) | 94.0 (63/67) | 0.21 |
| Viral load | |||
| ≥ 800.000 IU mL−1 | 89.8 (80/89) | 91.8 (34/37) | 0.72 |
| <800.000 IU mL−1 | 93.5 (73/78) | 92.5 (37/40) | 0.82 |
Note: Some groups have different number of patients compared to total number of patients as it occurred missing data in some baseline parameters presented in Table 1.
a
Comparison between SOF + DCV ± RBV versus SOF + SMV ± RBV patients for each group Abbreviations: DAC, daclatasvir; GT, genotype; NA, not applicable; NI, not informed; RBV, ribavirin SOF, sofosbuvir; SMV, simeprevir.